Pfizer 3Q net falls due to generics, higher costs

A sign for Pharmaceutical company Pfizer is displayed on 42 Street in New York October 20, 2009. Pharmaceutical industry leader Pfizer said Tuesday third-quarter profits rose 26 percent from a year ago to 2.88 billion dollars, as cost cuts helped offset lower revenues. The profit amounted to to 51 cents a share excluding special items, topping Wall Street consensus estimates of 48 cents.AFP PHOTO TIMOTHY A. CLARY (Photo credit should read TIMOTHY A. CLARY/AFP/Getty Images) TIMOTHY A. CLARY

Pfizer Inc. (PFE) says third-quarter profit dropped 19 percent as generic competition continued to cut sales, while operational expenses, taxes and charges all rose.

The maker of Lyrica for fibromyalgia says net income was $2.59 billion, or 39 cents per share, down from $3.21 billion, or 43 cents per share, a year earlier.

Excluding one-time items, the world's second-largest drugmaker says net income would have been $3.86 billion, or 58 cents per share. Analysts surveyed by FactSet expected 56 cents per share.

Revenue totaled $12.64 billion, down 2 percent from $12.95 billion a year ago. Analysts expected $12.69 billion.

New York-based Pfizer raised the lower end of its 2013 profit forecast by a nickel and now expects $2.15 to $2.20 per share.




Live Video

Market Data

Watch CBSN Live

Watch CBS News anytime, anywhere with the new 24/7 digital news network. Stream CBSN live or on demand for FREE on your TV, computer, tablet, or smartphone.

Watch Now

Market News

Stock Watchlist

New Android App

For your Android phone and tablet, download the FREE redesigned app, featuring CBSN, live 24/7 news.